πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Hepion Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Dynavax Technologies Corporation

Dynavax Technologies Corporation logo
Market Cap: High
Employees: Medium

HEPLISAV-B

Dynavax Technologies Corporation is a biopharmaceutical company focusing on the development and commercialization of novel vaccines, including HEPLISAV-B, a hepatitis B vaccine. It collaborates with several international partners and is headquartered in Emeryville, California.

Tags: HEPLISAV-B, biopharmaceutical, biotech, hepatitis B, pharmaceutical partnerships, vaccines

Symbol: DVAX

Recent Price: $12.83

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Ryan Spencer

Sector: Healthcare

Employees: 408

Address: 2100 Powell Street, EmeryVille, CA 94608

Phone: 510 848 5100

Last updated: 2024-12-31

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Rencofilstat

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drug therapies for chronic liver diseases, particularly through the development of Rencofilstat, a cyclophilin inhibitor aimed at treating non-alcoholic steatohepatitis (NASH) and reducing liver fibrosis and tumors.

Tags: NASH, Rencofilstat, biopharmaceutical, cyclophilin inhibitor, drug therapy, liver disease

Symbol: HEPA

Recent Price: $0.43

Industry: Biotechnology

CEO: Mr. John Patrick Brancaccio CPA

Sector: Healthcare

Employees: 22

Address: 399 Thornall Street, Edison, NJ 08837

Phone: 732 902 4000

Leadership

  • John P. Brancaccio, Interim Chief Executive Officer, Interim Chief Financial Officer, and Chairman of the Board

Last updated: 2024-12-31

Statera Biopharma, Inc.

Statera Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

STAT-201, Entolimod, STAT-401, STAT-205

Statera Bio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat autoimmune diseases, cancers, and infectious diseases by rebalancing the immune system.

Tags: autoimmune, biopharmaceutical, cancer, immune system, immunotherapy, infectious diseases, novel therapies

Symbol: STAB

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Michael Kevin Handley

Sector: Healthcare

Employees: 46

Address: 2537 Research Boulevard, Fort Collins, CO 80526

Phone: 888 613 8802

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Fadraciclib, CYC140, Sapacitabine, Seliciclib

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of medicines for treating cancer and other proliferative diseases. The company's key development programs include fadraciclib, CYC140, Sapacitabine, and seliciclib, targeting various forms of cancer and other conditions.

Tags: CDK inhibitors, biopharmaceutical, cancer treatment, clinical trials, proliferative diseases

Symbol: CYCC

Recent Price: $0.37

Industry: Biotechnology

CEO: Mr. Spiro George Rombotis

Sector: Healthcare

Employees: 12

Address: 200 Connell Drive, Berkeley Heights, NJ 07922

Phone: 908 517 7330

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

FibroGen, Inc.

FibroGen, Inc. logo
Market Cap: Lowest
Employees: Medium

Roxadustat, Pamrevlumab

Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.

Tags: anemia, antibody, biopharmaceutical, cancer, kidney disease, pulmonary fibrosis, therapeutics

Symbol: FGEN

Recent Price: $0.53

Industry: Biotechnology

CEO: Mr. Thane Wettig

Sector: Healthcare

Employees: 486

Address: 409 Illinois Street, San Francisco, CA 94158

Phone: 415 978 1200

Last updated: 2024-12-31

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

SUSTOL, CINVANTI, ZYNRELEF

Heron Therapeutics, Inc. is a biotechnology company focused on developing treatments to address unmet patient needs, utilizing its proprietary Biochronomer drug delivery technology.

Tags: biotechnology, cancer treatment, chemotherapy, drug delivery, nausea prevention

Symbol: HRTX

Recent Price: $1.51

Industry: Biotechnology

CEO: Mr. Craig Alexander Collard

Sector: Healthcare

Employees: 126

Address: 4242 Campus Point Court, San Diego, CA 92121

Phone: 858 251 4400

Leadership

  • Adam Morgan, Chairman
  • Sharmila Dissanaike, M.D., FACS, FCCM, Director
  • Craig Johnson, Lead Independent Director
  • Susan Rodriguez, Director
  • Christian Waage, Director
  • Craig Collard, Director
  • Brett Fleshman, Chief Business Officer

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • HervΓ© Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Anticalin-based drugs

Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on discovering and developing anticalin-based drugs for respiratory diseases, idiopathic pulmonary fibrosis, and cancer.

Tags: anticalin, biopharmaceutical, clinical trials, drug development, immuno-oncology, respiratory diseases

Symbol: PIRS

Recent Price: $13.60

Industry: Biotechnology

CEO: Mr. Stephen S. Yoder J.D.

Sector: Healthcare

Employees: 46

Address: 255 State Street, Boston, MA 02109

Phone: 857 246 8998

Last updated: 2024-12-31

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

PLN-74809

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.

Tags: biopharmaceutical, clinical trials, fibrosis, integrin inhibitor, therapies

Symbol: PLRX

Recent Price: $12.79

Industry: Biotechnology

CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Sector: Healthcare

Employees: 166

Address: 260 Littlefield Avenue, South San Francisco, CA 94080

Phone: 650 481 6770

Last updated: 2024-12-31

Renovaro Biosciences Inc.

Renovaro Biosciences Inc. logo
Market Cap: Lowest
Employees: Lowest

RENB-HV-01, RENB-HV-12, RENB-HB-01, RENB-DC-11, RENB-DC-12-XX, RENB-HV-21

Renovaro Biosciences Inc. is a pre-clinical stage biotechnology company focused on R&D of pharmaceutical and biological products for treating HIV, HBV, and cancer in the U.S. The company has a robust product pipeline and strategic partnerships, and was formerly known as Enochian Biosciences, Inc.

Tags: HBV treatment, HIV treatment, biotechnology, cancer treatment, pharmaceutical research, strategic partnerships

Symbol: RENB

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. David H. Weinstein

Sector: Healthcare

Employees: 25

Address: 2080 Century Park East, Los Angeles, CA 90067

Phone: 305 918 1980

Last updated: 2024-12-31

Sagimet Biosciences Inc.

Sagimet Biosciences Inc. logo
Market Cap: Low
Employees: Lowest

Denifanstat

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics called fatty acid synthase (FASN) inhibitors for diseases caused by dysfunctional lipid metabolism pathways. Its lead drug candidate, Denifanstat, targets nonalcoholic steatohepatitis and acne. The company is also working on FASN inhibitors for cancer treatment.

Tags: Denifanstat, FASN inhibitors, acne, biopharmaceutical, cancer, nonalcoholic steatohepatitis

Symbol: SGMT

Recent Price: $4.72

Industry: Biotechnology

CEO: Mr. David A. Happel

Sector: Healthcare

Employees: 8

Address: 155 Bovet Road, San Mateo, CA 94402

Phone: 650-561-8600

Leadership

  • George Kemble, PhD, Executive Chairman of the Board
  • David Happel, Chief Executive Officer
  • Anne Phillips, MD,
  • Beth Seidenberg, MD,
  • Elizabeth Grammer, Esq,
  • Jennifer Jarrett,
  • Merdad Parsey, MD, PhD,
  • Paul Hoelscher,
  • Tim Walbert,

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Medium

RNA-targeted therapeutics

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.

Tags: ALS, Biotechnology, Pharmaceuticals, RNA therapeutics, SPINRAZA, TEGSEDI, TTR amyloidosis, WAYLIVRA

Symbol: IONS

Recent Price: $34.92

Industry: Biotechnology

CEO: Dr. Brett P. Monia Ph.D.

Sector: Healthcare

Employees: 927

Address: 2855 Gazelle Court, Carlsbad, CA 92010

Phone: 760 931 9200

Last updated: 2024-12-31